Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Hypothesis: the Telaprevir(TVR) plasma levels (750 mg q8h or 1125 mg/12h )will not be
affected when co-administered with un-boosted Atazanavir (ATV) 200 mg q12h plus two analogues
(NRTIs) in HCV/HIV-co-infected patients.